5,319 Shares in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Acquired by Rothschild Asset Management Inc.

Rothschild Asset Management Inc. purchased a new position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 5,319 shares of the biopharmaceutical company’s stock, valued at approximately $647,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nicolet Bankshares Inc. purchased a new position in Alexion Pharmaceuticals during the second quarter worth approximately $347,000. Janney Montgomery Scott LLC boosted its position in Alexion Pharmaceuticals by 62.1% in the second quarter. Janney Montgomery Scott LLC now owns 13,541 shares of the biopharmaceutical company’s stock worth $1,648,000 after buying an additional 5,186 shares during the period. Harbour Capital Advisors LLC boosted its position in Alexion Pharmaceuticals by 712.3% in the second quarter. Harbour Capital Advisors LLC now owns 28,592 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 25,072 shares during the period. IBM Retirement Fund boosted its position in Alexion Pharmaceuticals by 119.7% in the second quarter. IBM Retirement Fund now owns 5,325 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 2,901 shares during the period. Finally, NGAM Advisors L.P. boosted its position in Alexion Pharmaceuticals by 24.5% in the second quarter. NGAM Advisors L.P. now owns 16,953 shares of the biopharmaceutical company’s stock worth $2,063,000 after buying an additional 3,335 shares during the period. Institutional investors own 95.14% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 132.30 on Friday. The firm has a market capitalization of $29.53 billion, a PE ratio of 57.37 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $145.42. The firm has a 50-day moving average price of $129.17 and a 200-day moving average price of $122.91.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. During the same quarter in the previous year, the business posted $1.13 EPS. The firm’s revenue was up 21.1% compared to the same quarter last year. On average, analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2801817/5319-shares-in-alexion-pharmaceuticals-inc-nasdaqalxn-acquired-by-rothschild-asset-management-inc.html.

A number of research firms have commented on ALXN. BidaskClub upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target on the stock in a research note on Wednesday, August 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $168.00 price objective (up from $159.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Leerink Swann increased their price objective on Alexion Pharmaceuticals from $136.00 to $170.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. upgraded Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price objective on the stock in a research note on Friday, July 28th. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $156.89.

In other news, CEO Ludwig Hantson acquired 10,000 shares of the business’s stock in a transaction on Wednesday, June 14th. The shares were purchased at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the acquisition, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at approximately $4,519,982. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the transaction, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Insiders acquired a total of 2,019,734 shares of company stock worth $235,606,846 in the last quarter. 4.35% of the stock is currently owned by company insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.